Page 52 - Read Online

Hewitt et al. Hepatoma Res 2021;7:75 https://dx.doi.org/10.20517/2394-5079.2021.83 Page 15 of 19

11. Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992;215:31-8.
DOI PubMed PMC
12. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann
Surg 2001;234:507-17; discussion 517-9. DOI PubMed PMC
13. Matsuo K, Rocha FG, Ito K, et al. The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability
and outcomes in 380 patients. J Am Coll Surg 2012;215:343-55. DOI PubMed
14. Chaiteerakij R, Harmsen WS, Marrero CR, et al. A new clinically based staging system for perihilar cholangiocarcinoma. Am J
Gastroenterol 2014;109:1881-90. DOI PubMed PMC
15. Nguyen Canh H, Takahashi K, Yamamura M, et al. Diversity in cell differentiation, histology, phenotype and vasculature of mass-
forming intrahepatic cholangiocarcinomas. Histopathology 2021;79:731-50. DOI PubMed
16. Deoliveira ML, Schulick RD, Nimura Y, et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology
2011;53:1363-71. DOI PubMed
17. Yamashita S, Morine Y, Imura S, et al. A new pathological classification of intrahepatic cholangiocarcinoma according to protein
expression of SSTR2 and Bcl2. World J Surg Oncol 2021;19:142. DOI PubMed PMC
18. Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States:
a population-based case-control study. Clin Gastroenterol Hepatol 2007;5:1221-8. DOI PubMed PMC
19. Jing W, Jin G, Zhou X, et al. Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev
2012;21:24-31. DOI PubMed
20. Sahani D, Prasad SR, Tannabe KK, Hahn PF, Mueller PR, Saini S. Thorotrast-induced cholangiocarcinoma: case report. Abdom
Imaging 2003;28:72-4. DOI PubMed
21. McGee EE, Jackson SS, Petrick JL, et al. Smoking, alcohol, and biliary tract cancer risk: a pooling project of 26 prospective studies. J
Natl Cancer Inst 2019;111:1263-78. DOI PubMed PMC
22. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver
cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011;54:463-71. DOI PubMed PMC
23. Kubo S, Kinoshita M, Takemura S, et al. Characteristics of printing company workers newly diagnosed with occupational
cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2014;21:809-17. DOI PubMed
24. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol
2002;36:321-7. DOI PubMed
25. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995;332:924-33. DOI PubMed
26. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing
cholangitis. J Hepatol 2009;50:158-64. DOI PubMed
27. Lipsett PA, Pitt HA, Colombani PM, Boitnott JK, Cameron JL. Choledochal cyst disease. A changing pattern of presentation. Ann
Surg 1994;220:644-52. DOI PubMed PMC
28. Khan SA, Thomas HC, Davidson BR, Taylor-robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303-14. DOI PubMed
29. Roukounakis N, Manolakopoulos S, Tzourmakliotis D, Bethanis S, McCarty TM, Cuhn J. Biliary tract malignancy and abnormal
pancreaticobiliary junction in a Western population. J Gastroenterol Hepatol 2007;22:1949-52. DOI PubMed
30. Watanapa P, Watanapa WB. Liver fluke-associated cholangiocarcinoma. Br J Surg 2002;89:962-70. DOI PubMed
31. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a
case-control study. Gastroenterology 2005;128:620-6. DOI PubMed
32. Kobayashi M, Ikeda K, Saitoh S, et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with
hepatitis C virus-related cirrhosis. Cancer 2000;88:2471-7. DOI PubMed
33. Hsing AW, Zhang M, Rashid A, et al. Hepatitis B and C virus infection and the risk of biliary tract cancer: a population-based study
in China. Int J Cancer 2008;122:1849-53. DOI PubMed
34. Mecklin JP, Järvinen HJ, Virolainen M. The association between cholangiocarcinoma and hereditary nonpolyposis colorectal
carcinoma. Cancer 1992;69:1112-4. DOI PubMed
35. Lee SS, Kim MH, Lee SK, et al. Clinicopathologic review of 58 patients with biliary papillomatosis. Cancer 2004;100:783-93. DOI
PubMed
36. Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A. Risk of gastrointestinal cancers in patients with cystic fibrosis: a
systematic review and meta-analysis. Lancet Oncol 2018;19:758-67. DOI PubMed
37. Chen XX, Yin Y, Cheng JW, et al. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2
and JNK/c-Jun pathways. Cell Death Dis 2018;9:1036. DOI PubMed PMC
38. Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol 1999;10 Suppl 4:308-11. PubMed
39. Akiba J, Nakashima O, Hattori S, et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the
latest WHO classification. Am J Surg Pathol 2013;37:496-505. DOI PubMed
40. Labib PL, Goodchild G, Pereira SP. Molecular pathogenesis of cholangiocarcinoma. BMC Cancer 2019;19:185. DOI PubMed
PMC
41. Jones H, Alpini G, Francis H. Bile acid signaling and biliary functions. Acta Pharm Sin B 2015;5:123-8. DOI PubMed PMC
42. Chen B, Liu J, Ho TT, Ding X, Mo YY. ERK-mediated NF-κB activation through ASIC1 in response to acidosis. Oncogenesis
2016;5:e279. DOI PubMed PMC
43. Araki K, Shimura T, Suzuki H, et al. E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal
transition in extrahepatic cholangiocarcinoma. Br J Cancer 2011;105:1885-93. DOI PubMed PMC